Skip to main content
Premium Trial:

Request an Annual Quote

In Brief This Week: Caliper Life Sciences; Interleukin Genetics; EMD Millipore; Waters; BioFocus

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Caliper Life Sciences this week said that the UK's Genome Analysis Centre, TGAC, will showcase its instrumentation for automated next-generation sequencing sample preparation and serve as a national reference site. Caliper said it will install at TGAC its NGS Bundle, which consists of its Sciclone NGS Workstation for library construction, the LabChip GX for library quantification and quality control, and the preparative LabChip XT for DNA size selection.


Interleukin Genetics has entered into an agreement to identify predictive biomarkers for use with Metagenics' Meta-060, which is being developed for weight management.


EMD Millipore, the life science division of Germany's Merck KGaA, has opened a new Biopharmaceutical Technical and Training Center in Shanghai, China. The center will provide support, training, and validation services to EMD Millipore's biopharmaceutical customers in China.


Waters said this week that it has designated the Proteomics Core Facility at Duke University School of Medicine as one of its Centers of Innovation. In previously launching the program, Waters recognized labs at Northeastern University, Imperial College London, the University of California-Davis, the university of Warwick, and Kings College London.


BioFocus this week said that it will use its SilenceSelect target discovery platform to validate drug targets in Astellas Pharma's neurology pipeline. BioFocus said that it would receive research funding and success payments based on progression of the collaboration.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.